TheraP Study: Lu-PSMA vs. cabazitaxel #ASCO20 #ANZUP
2.3 هزار بار بازدید -
4 سال پیش
-
A randomised phase II trial
A randomised phase II trial of 177Lu-PSMA-617 (Lu-PSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results
Presented by Professor Michael Hofman on behalf of co-authors:
Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony Joshua, Jeffrey Goh, David Pattison, Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn Francis, Craig Gedye, Natalie Rutherford, Alison Zhang, Margaret McJannett, Martin Stockler, John Violet, Scott Williams, Andrew Martin, Ian Davis
TheraP is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) in collaboration with the NHMRC CTC and the Australasian Radiopharmaceutical Trials Network (ARTnet) with support from the Australian Nuclear Science and Technology Organisation (ANSTO) and Endocyte Inc., a Novartis company.
Clinicaltrials.gov NCT03392428
Presented by Professor Michael Hofman on behalf of co-authors:
Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony Joshua, Jeffrey Goh, David Pattison, Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn Francis, Craig Gedye, Natalie Rutherford, Alison Zhang, Margaret McJannett, Martin Stockler, John Violet, Scott Williams, Andrew Martin, Ian Davis
TheraP is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) in collaboration with the NHMRC CTC and the Australasian Radiopharmaceutical Trials Network (ARTnet) with support from the Australian Nuclear Science and Technology Organisation (ANSTO) and Endocyte Inc., a Novartis company.
Clinicaltrials.gov NCT03392428
4 سال پیش
در تاریخ 1399/05/31 منتشر شده
است.
2,399
بـار بازدید شده